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Editorial
Introduction of high-throughput measurement technolo-
gies combined with the increase of the scientific knowl-
edge base, with respect to our understanding of cellular
and biological processes, resulted in establishing compu-
ter and information science as an important and funda-
mental component of modern biology. High-throughput
measurement technologies, such as microarray-based
profiling, mass spectrometry screens, and high-through-
put sequencing, give rise to several computational chal-
lenges. On one hand, they require a rigorous approach
to assay design. Scientists and technology developers
work on optimizing assay components so as to maxi-
mize the information obtained through the measure-
ment. On the other hand, the use of high-throughput
measurement gives rise to large quantities of data that
needs to be pre-processed and analyzed to obtain mean-
ingful knowledge. This processing and analysis is per-
formed on various levels - from pre-processing the raw
data, such as images from microarrays or raw sequence
reads - to analyzing the data and to the discovery of bio-
markers or other biologically meaningful characteristics.
Measurement technology addresses several aspects of
cellular processes such as DNA, RNA, proteomics,
metabolomics, epigenetics and pathways. This increase
in the scientific knowledge base also leads to a central
role played by data analysis and modeling, strongly
grounded in computational methods. Systems biology or
integrative biology approaches and network analysis are
of specific importance in this context.
The above is even further emphasized in the context
of cancer research. Samples are complex and heteroge-
neous, and cancer related mechanisms involve many
layers of the process that leads from the genome to cel-
lular function. One example of a specific need of cancer
is the study of large scale aberrations in the genome.
CNVs (copy number variations) were recently
recognized as abundant in normal cell populations and
as related to many other disease types but they are still
a hallmark of cancer [1,2]. Genomes in cancer cells
often have a structure that allows them to bypass
growth control cellular processes. Regions coding for
tumor suppressor genes are often deleted and regions
harboring oncogenes may be amplified. This is the case,
for example, for p16 and myc, respectively [3-5]. Rear-
rangements, such as inversions and translocations, give
rise to tumor-driving fusion products as in the case of
BCR-Abl and the Philadelphia Chromosome as well as
in more recent findings implicating fusion structures in
solid tumors. Cancer research therefore makes use of
data analysis methods and tools that address interpreta-
tion of copy number data and the understanding of the
effect of genome changes on transcriptome level as well
as proteome level profiles of tumors. Other specific
computational needs of cancer research are related to
epigenetic changes, somatic evolution, definition of gene
sets in the context of specific cancer types, and to drugs
and data that measures the effects of drugs.
Computational biologists focusing on cancer develop
methods for the genome scale characterization of tumors,
on various levels of the molecular process. Data analysis
methods often rely on the analysis of high-throughput
measurement data and they provide understanding of the
relationship between various molecular characteristics of
cells. For example - how do genome structural aberra-
tions and changes in copy number, a result of increased
genome instability in cancer, affect the expression of
genes and other functional elements such as miRNA, and
how do the latter changes affect the function of related
proteins. Understanding of the association of genomic
characteristics and clinical properties of primary tumor
samples, xenografts or cell lines contributes to persona-
lized cancer medicine through the development of pre-
dictive biomarkers of drug efficacy. Many research
projects therefore aim to discover biomarkers, at either
genome, transcriptome or proteome level that are prog-
nostic of cancer progression or predictive of response to
specific therapeutic agents [6,7]. Cancer computational
biology also focuses on analyzing molecules and
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the analysis of cell cycle regulatory proteins and of
immune response elements through the use of mathema-
tical network and correlation models (For example - [8]).
Many resources, such as IMEx [9], I2D [10], KEGG [11],
PathwaysCommons [12], Reactome [13], i-HOP [14],
STRING [15], GeneCards [16], mirDIP [17] and tools like
Cytoscape [18], GSEA [19], NAViGaTOR [20] and GOr-
illa [21] provide some of the necessary bioinformatics
infrastructure for integrative cancer research. Figure 1
exemplifies the integration of a cancer gene list from
Sanger CENSUS data, highlighted within the human pro-
tein-protein interaction network.
The meeting and the papers in this collection
RECOMB Cancer Computational Biology (RCCB) is a
RECOMB satellite workshop that focuses on compu-
tational, statistical and algorithmic questions related
to cancer. RCCB 2010 http://bioinfo.cs.technion.ac.il/
people/zohar/recombccb2010/ took place in Oslo,
Norway, adjacent to the biannual meeting of the Eur-
opean Association for Cancer Research (EACR). This
meeting followed the first RCCB, which was held in
San Diego in 2007. In 2011 RCCB will be held in
conjunction with the main RECOMB conference in
Vancouver; http://compbio.cs.sfu.ca/recomb2011/
satellite/.
Figure 1 Human interactome from I2D ver. 1.9 http://ophid.utoronto.ca/i2d - 278,214 physical protein-protein interaction (of which
158,549 are unique), connecting 14,641 proteins. Using concentric circle layout, Sanger CENSUS cancer genes are used as a root (523
proteins connected directly by 1,180 interactions), and proteins with fewer than 51 interacting partners are collapsed in the two central points
(to reduce number of objects and make the resulting SVG file editable in Adobe Illustrator). Node size corresponds to node degree, and node
color corresponds to GeneOntology biological function. Visualization was done in NAViGaTOR ver. 2.2.1 http://ophid.utoronto.ca/navigator.
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benefits from close collaboration among diverse disci-
plines - computational biology, cancer research, geno-
mics, proteomics to name a few. This collaboration also
manifested itself in the meeting, bringing together speak-
ers and attendees from various disciplines. The full pro-
gram and to video recordings of many of the talks are
listed on the meeting’s website http://bioinfo.cs.technion.
ac.il/people/zohar/recombccb2010/program.html. We
will highlight three of the thematic foci of the meeting:
￿ Cancer and copy number instability. Chromoso-
mal instability and changes in copy number are
amongst the most important hallmarks of cancer. In
many cases copy number differences drive differ-
ences in clinical behavior and in susceptibility to
treatments. The understanding of the structure of
chromosomal aberrations in cancer requires accurate
measurement technologies coupled with data analy-
sis and interpretation tools. Chris Greenman, from
Wellcome Trust Sanger Institute, described an algo-
rithmic approach to studying the evolution of geno-
mic instability in cancer, through the analysis of
sequencing data. In particular these methods attempt
to infer orders of occurrence for observed aberra-
tions, both mutations and copy number changes.
Peter van Loo, from KU Leuven, described ASCAT -
a tool for analyzing allele-specific copy number data,
and discussed some results obtained for a breast
cancer cohort. These include differences between
various breast cancer subtypes. Basal-like samples
were found to have significantly higher frequency of
LOH compared to the other types. Hiroko Solvang,
from Oslo University Hospital, talked about the rela-
tionship between copy number and expression levels
[22]. Yinyin Yuan, from Cambridge University,
described an approach to studying the regulation
relationship between copy number and expression
when focusing on specific disease subtypes, e.g., ER-
positive and ER-negative samples. Finally, Anna Ritz,
from the Computer Science Department in Brown
University, described an algorithmic approach to
determining genomic structure from high-through-
put copy number data [23]. This approach considers
recurrent events in datasets with multiple samples.
While other approaches study common aberrations,
the Ritz et al. approach identifies recurrent break-
points, and thereby infers potential fusion and gene
truncation events. Such events are obviously extre-
mely relevant to cancer pathogenesis and develop-
ment processes, and the Ritz et al. method enables
an analysis that may lead to significant findings.
￿ Systems biology approach to cancer. Three key-
note talks addressed studies that consider the full
system level properties of cancer and what can be
learned from them. Joe Gray’s Lab, at LBNL, worked
with 50+ breast cancer cell lines and ~80 different
compounds targeting the ERBB2 pathway, generating
IC50 data for these combinations and inferring
genomic determinants of treatment efficiency. Yossi
Yarden’s Lab, at the Weizmann Institute, studied the
response to EGF stimulus, measuring both the tran-
scriptome reaction and a comprehensive miRNA
reaction. A talk at the meeting described some of
these results in the context of previous studies of
the EGF pathway. Special emphasis was put on miR-
NAs that are immediately down-regulated in
response to the signal. Israel Steinfeld, from the
Technion in Haifa, described a breast cancer study
integrating miRNA and mRNA profiles that further
expands our understanding of miRNA activity in
cancer. This includes the association of processes
such as proliferation and cell cycle to the activity of
miRNAs and their target genes. High-throughput
proteomics profiling, including the understanding of
a c t i v a t i o ns t a t u s ,c a nb ea ni m p o r t a n tp i e c ei nt h e
cancer system biology picture, including implications
for direct targeted therapy. The realization of this
potential requires accurate and high-throughput pro-
teomics measurement technologies as well as data
analysis techniques to support interpretation and
inference. Gordon Mills, from MD Anderson Cancer
Centre, described the ongoing work he and collea-
gues are doing on developing and optimizing
Reverse Phase Protein Arrays (RPPAs), and on using
them in cancer-related studies.
￿ Networks. Understanding the relationship between
various molecular elements can extend the under-
standing of larger scale processes and thereby
expand the repertoire of molecules related to cancer.
Anaise Baudot, from CNIO (Centro Nacional de
Investigaciones Oncológicas), presented her joint
work with Enrico Glaab and others on extending
functional annotation networks using information
derived from protein-protein interaction networks
[24]. They map proteins annotated for different cel-
lular processes onto a large protein-protein interac-
tion networks and attempt to extend these processes
by adding the most densely interconnected network
partners, when said connectivity exceed certain
threshold criteria. Gurkan Bebek, Case Western
Reserve University, described a process that enables
the prioritization of various mutation states in a key
gene, according to their effect on protein levels, in
specific contexts, most notable in the context of a
specific cancer type. The performance of the soft-
ware, called PETALS, was demonstrated through the
analysis of APC as a driver of colon cancer [25].
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thematic collection we present the papers that were pre-
sented as talks in Oslo and were also selected, through
an additional co-ordinated review process, to be pub-
lished by BMC Bioinformatics [22-25].
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